文献速递衰弱、肌少症与跌倒认知障碍与谵妄安宁疗护

养老院临终老年退伍军人抗高血压药物减处方的真实世界模式

Antihypertensive Deprescribing in Older Adult Veterans at End of Life Admitted to Veteran Affairs Nursing Homes.
PubMed 文献 · J Am Med Dir Assoc · 2020-07-25

该研究为全国性回顾性队列,纳入2009-2015财年入住VA养老院、预期寿命有限和/或晚期痴呆且高血压过度治疗的老年退伍军人共10574例。结果显示30天减处方累积发生率为41%,过度治疗程度最高者减处方可能性更大(HR 1.75,95%CI 1.59-1.93),不良预后标志与较晚入院年份增加减处方可能,而心血管危险因素等降低其可能。

要点

  • 30天抗高血压减处方累积发生率为41%。
  • 过度治疗程度最高者减处方可能性更高(HR 1.75,95%CI 1.59-1.93)。
  • 不良预后标志与较晚入院年份增加减处方可能,心血管危险因素降低其可能。

核心结论

  • 养老院高血压且预期寿命有限和/或晚期痴呆居民的抗高血压减处方真实模式反映了治疗强度建议的差异和个体化医疗。
  • 促进减处方的因素包括治疗强度和不良预后标志。
  • 需要比较有效性和安全性研究来指导减处方和高血压管理的临床决策。

研究设计与样本

  • 全国性回顾性队列研究。
  • 纳入2009-2015财年入住VA养老院、预期寿命有限和/或晚期痴呆且高血压过度治疗的老年退伍军人,共10574例。
  • 过度治疗定义为入院时接受至少1类抗高血压药物且平均每日收缩压<120 mm Hg。
  • 减处方定义为随后剂量减少或停用抗高血压药≥7天。
  • 采用竞争风险模型评估累积发生率和相关因素。

主要发现

  • 30天减处方累积发生率为41%。
  • 过度治疗程度最高者(多类抗高血压药且收缩压<100 mm Hg)相比最低者(1类抗高血压药且收缩压≥100至<120 mm Hg)减处方可能性增加(HR 1.75,95%CI 1.59-1.93)。
  • 近期体重下降、食欲差、脱水、日常生活活动依赖、疼痛等不良预后标志与较晚入院年份与减处方可能性增加相关。
  • 糖尿病、充血性心力衰竭、肥胖等心血管危险因素、气短、以及来自其他养老院或家庭/辅助生活场所(相比急诊医院)与减处方可能性降低相关。

关键数值与推荐

  • 过度治疗定义:入院时接受至少1类抗高血压药物且平均每日收缩压<120 mm Hg。
  • 减处方定义:随后剂量减少或停用抗高血压药≥7天。
  • 过度治疗程度最高者减处方HR 1.75(95%CI 1.59-1.93),对照为最低程度者。

临床怎么用

  • 对预期寿命有限和/或晚期痴呆的养老院高血压居民,可考虑评估过度治疗并个体化减处方。
  • 治疗强度高和存在不良预后标志(如体重下降、食欲差、脱水、ADL依赖、疼痛)者可能更适合减处方。
  • 合并心血管危险因素(糖尿病、心衰、肥胖)或气短者减处方需更谨慎权衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Geriatric palliative care approaches support deprescribing of antihypertensives in older nursing home (NH) residents with limited life expectancy and/or advanced dementia (LLE/AD) who are intensely treated for hypertension (HTN), but information on real-world deprescribing patterns in this population is limited. We examined the incidence and factors associated with antihypertensive deprescribing. DESIGN: National, retrospective cohort study. SETTING AND PARTICIPANTS: Older Veterans with LLE/AD and HTN admitted to VA NHs in fiscal years 2009-2015 with potential overtreatment of HTN at admission, defined as receiving at least 1 antihypertensive class of medications and mean daily systolic blood pressure (SBP) <120 mm Hg. MEASURES: Deprescribing was defined as subsequent dose reduction or discontinuation of an antihypertensive for ≥7 days. Competing risk models assessed cumulative incidence and factors associated with deprescribing. RESULTS: Within our sample (n = 10,574), cumulative incidence of deprescribing at 30 days was 41%. Veterans with the greatest level of overtreatment (ie, multiple antihypertensives and SBP <100 mm Hg) had an increased likelihood (hazard ratio 1.75, 95% confidence interval 1.59, 1.93) of deprescribing vs those with the lowest level of overtreatment (ie, one antihypertensive and SBP ≥100 to <120 mm Hg). Several markers of poor prognosis (ie, recent weight loss, poor appetite, dehydration, dependence for activities of daily living, pain) and later admission year were associated with increased likelihood of deprescribing, whereas cardiovascular risk factors (ie, diabetes, congestive heart failure, obesity), shortness of breath, and admission source from another NH or home/assisted living setting (vs acute hospital) were associated with decreased likelihood. CONCLUSIONS AND IMPLICATIONS: Real-world deprescribing patterns of antihypertensives among NH residents with HTN and LLE/AD appear to reflect variation in recommendations for HTN treatment intensity and individualization of patient care in a population with potential overtreatment. Factors facilitating deprescribing included treatment intensity and markers of poor prognosis. Comparative effectiveness and safety studies are needed to guide clinical decisions around deprescribing and HTN management.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Vu M, Sileanu FE, Aspinall SL, et al. Antihypertensive Deprescribing in Older Adult Veterans at End of Life Admitted to Veteran Affairs Nursing Homes. J Am Med Dir Assoc. 2020. PMID: 32723537. doi:10.1016/j.jamda.2020.05.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。